Bejelentkezés Regisztrálj ingyen

Cellectis Bevétel Y / Y

Mi az Cellectis Bevétel Y / Y?

A Bevétel Y / Y az Cellectis - -53.05%

Mi a Bevétel Y / Y meghatározása?

Az elmúlt 3 évben az éves bevételnövekedés a bevételek növekedése az elmúlt 3 év átlagában az elmúlt 3 évben.

The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.

Bevétel Y / Y a Health Care szektor a NASDAQ-on cégekben a Cellectis -hoz képest

Mit csinál Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

bevétel y / y -hoz hasonló cégek Cellectis